Pipeline

March 6, 2020
Company Drug/Device Medical Condition Status
MiNa Therapeutics MTL-CEBPA in combination with Keytruda (pembrolizumab) advanced solid tumors initiation and first patient treated in phase 1/1b trial
TargoVax SA ONCOS-102 in combination with Keytruda (pembrolizumab) advanced anti-PD1 checkpoint inhibitor (CPI) refractory melanoma patient enrollment completed in phase 1 trial
HUYA Bioscience International HBI-3000 cardioversion of atrial fibrillation completion of phase 1 trial
Dynacure DYN101 myotubular and centronuclear myopathies first patient dosed in phase 1/2 trial
Allergan plc

Editas Medicine		 AGN-151587 (EDIT-101) Leber congenital amaurosis 10 (LCA10) first patient dosed in phase 1/2 trial
Arrowhead Pharma ARO-HSD patients with NASH or suspected NASH first patients dosed in phase 1/2 trial
DiscGenics IDCT, allogeneic, injectable discogenic cell therapy degenerative disc disease completed enrollment in phase 1/2 trial
Novus Therapeutics OP0201 pediatrics with acute otitis media completed enrollment in phase 2a trial
VBI Vaccines VBI-1901 in combination with either GM-CSF or AS01B, (GlaxoSmithKline) recurrent GBM first patient dosed in the second study arm of phase 2a trial
Innovent Biologics IBI375 (pemigatinib) advanced cholangiocarcinoma with FGFR2 fusions or rearrangements first patients dosed in phase 2 trial
Neuraly NLY01 Parkinson’s disease first patient dosed in phase 2 trial
Moderna mRNA-1647 cytomegalovirus completed enrollment in phase 2 trial
American BriVision ABV-1505 adult attention-deficit hyperactivity disorder initiation of phase 2 trial
EpicentRx AIM-001 tumors IND approved by FDA
Prevail Therapeutics PR006 frontotemporal dementia patients with GRN mutation IND approved by FDA
Ayala Pharmaceuticals AL101 recurrent or metastatic adenoid cystic carcinoma Fast Track designation granted by FDA
Genentech Esbriet (pirfenidone) adults with unclassifiable interstitial lung disease Breakthrough Therapy Designation granted by FDA
Sanofi Sarclisa (isatuximab-irfc) in combination with pomalidomide and dexamethasone (pom-dex) adults with multiple myeloma who have had two previous therapies including lenalidomide and a protease inhibitor approved by the FDA

 

Upcoming Events

Featured Products

Featured Stories

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here